

# 23 - 24 June 2025 **Basel**, Switzerland



#### **Day 1 Track 1: Small Molecule Formulation**

- Overcoming challenges in small molecule drug formulation
- Formulation of novel drug modalities: PROTACs, Molecular Glues
- Recent advances to improve bioavailability: permeability, solubility
- Digitalization and automation of processes: Al/ML, in-silico modelling

### Day 1 Track 2: Large Molecule Delivery

- Moving beyond injectable delivery of biologics
- Lipid nanoparticles to deliver biologics
- Nanobodies as delivery vectors
- Overcoming oral delivery challenges
- Pre-filled syringes
- Vaccine delivery technologies

#### **Day 1 Track 3: Preformulation Studies**

- Solubility & stability analysis
- Characterizing chemical and physical properties
- Technologies for preformulation studies in pharmaceutical product
- development
- Bioanalytical methods improving drug product development

### Day 1 Track 4: RNA Design & Delivery

- Overcoming challenges in RNA delivery
- Advanced techniques for delivery beyond the liver
- Use cases of utilizing viral and non-viral delivery modalities
- Novel strategies for RNA design

#### **Day 2 Track 1: Large Molecule Formulation**

- Innovative formulation strategies for ADCs, cell & gene therapies and more
- Overcoming challenges in large molecule drug formulation
- Drug optimization to meet safety & efficacy requirements

#### Day 2 Track 2: Small Molecule Drug Delivery

- Oral dosage form improvement
- Novel routes of administration for small molecules: pulmonary, transdermal, topical, ocular
- Patient-friendly delivery and dosage forms
- Utilizing nanotechnology approaches

### Day 2 Track 3: Process Chemistry & Pharmaceutical Materials Analysis

- Effective selection and manufacturing of APIs
- Choosing the correct excipient for your drug
- Meeting sustainability criteria in product development
- Quantifying and understanding physical form of active ingredients
- Utilizing cutting-edge technologies for analysis & quality control: diffraction, thermal methods, vibrational spectroscopy, in process analytics
- Analytical characterization for testing APIs, excipients, blends and final solid dosage forms
- Methods to assess impurities
- Importance of early solid state chemistry

#### Day 2 Track 4: Peptide & Oligo Design & Delivery

- Drug delivery through the BBB
- Moving beyond oral delivery
- Innovative technologies, like needle-free injections, AI & microneedles
- Harnessing inherent potency of peptides with long-acting injectables and depositions
- Lipid-based formulations for oligonucleotide delivery
- Delivery of nucleic acids to cellular targets

Meet and learn from the key innovators and thought leaders in formulation & drug delivery. 2024 attendees included: Senior Director, Takeda; Executive Director, Novartis; Director of Stability Sciences, Janssen

**Benefits of Attending** 

- $\checkmark$ NEW TO 2025! Explore the novel strategies and developments in RNA design and delivery. Our expert speakers will be presenting on delivery beyond the liver, viral and non-viral delivery modalities and overcoming challenges in delivery
  - Benefit from a 2-day featured programme on small molecule drug formulation & delivery. Key opinion leaders will be presenting on PROTACs, latest advancements in enhancing bioavailability and nanotechnology approaches as well as formulation strategies for cell & gene therapies, lipid nanoparticles and the latest in vaccine delivery technologies

✓ NEW TO 2025! Join thought-leaders in advances, analysis and characterisation in process chemistry and Peptide & Oligo design and delivery. Hear how to move away from oral delivery and the latest on lipidbased formulations, manufacturing of APIs and innovative technologies

NEW TO 2025! Co-located with Discovery Europe 2025 to attract over 1000 senior-level attendees

#### Speakers Included:







AbbVie

#### **Meet Senior Decision Makers**

1000 senior attendees from leading research & academic institutions, clinical research institutions, food & nutrition companies as well as major pharmaceutical and biotech companies will attend the event. Delegate job titles include:

Formulation Science	Bioanalysis
Drug Delivery	Device Development
Preformulation Studies	Process Chemistry
Process Engineering	Pharmaceutical Sciences
RNA Delivery	Nanomedicine
Pharmaceutics	Analytical Chemistry

#### **Discover New Solutions**

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Services to be discussed include:

Contract Development	Raw Materials
Characterization Tools	Analytical Services
Effective Excipients	Solubility & Stability Testing
Dosage Forms	Quality Control
Delivery Devices	Controlled Release
Formulation Development	GMP Manufacturing

Andreas Gryczke

Sorina Morar-Mitrica Novartis

Vineeta Tripathi Vitarka Therapeutics

### **Discovery & Development 2025 Sponsors:**

Platinum Sponsors:



### Formulation & Delivery Europe 2025 Speakers:

### Pharma & Biotech

- Ulrich Betz, Vice President Innovation, Merck
- Tanvir Tabish, Director, Early Formulation Development, AstraZeneca
- Andreas Gryczke, Director, Process Engineering, AbbVie
- Maria Levitin, Director of RNA Oligonucleotide Delivery, Genetic Medicine, Grünenthal
- Holger Kubas, Head of Early Stage Development, Merck
- Sophie Janbon, Director, AstraZeneca
- Sorina Morar-Mitrica, Director Science & Technology, Novartis
- Simone Tortoioli, Senior CMC Director, Monte Rosa Therapeutics
- Jens Twellmeyer, Associate Director Science & Technology, Novartis
- Simone Vecchi, Associate Director of Drug Product Development, Johnson & Johnson Innovative Medicine
- Shayoni Dutta, Data Science Manager, GSK
- Farshad Ramazani, Senior Expert Science & Technology, Novartis
- Eric Lorent, Principal Scientist, Sanofi
- Meiling Li, Principal Scientist, Roche
- Meike Harms, Lead Scientist, Enabling Development, Merck
- Juha Monkare, Senior Scientist, Johnson & Johnson Innovative Medicine
- Suruchi Vishwasrao, Senior Scientist, Merck
- Jessica Yu, Senior Scientist, AstraZeneca
- Supriyadi Hafiz, Senior Scientist, Merck
- Florian Ries, Senior Scientist, AbbVie
- Enrico Zambelli, Sustainable Formulation Project Unit Manager, Chiesi
- Joël Richard, Chief Development Officer, Enterome SA
- Heinrich Haas, Chief Technology Officer, NeoVac
- Vineeta Tripathi, Chief Executive Officer, Vitarka Therapeutics
- Dan Hardy, Chief Executive Officer, Microsol
- Shadi Farhangrazi, Chief Executive Officer, S.M. Discovery Group
- Stephen Pham, Senior Vice President, Avalyn Pharma
- Sandor Batkai, Co-founder, Head of Medical Research and Intelligence, Cardior Pharmaceuticals
- Covadonga Paneda, Chief Operating Officer, Altamira Therapeutics
- Estelle Beguin, Director Technology Research, Ethris
- Ramesh Kashi, Senior Scientific Director Sterile Product Development
- Daniel Tondera, Head of Biology, Pantherna Therapeutics
- Katarzyna Malik, Research and Development Director, Polpharma
- Saif Shubber, Associate Director, Bicycle Therapeutics
- Tjasa Vrlinic, Principal Investigator, Medincell
- Vik Reebye, Senior Principal Scientist, Head of Academic Partnership, MiNA Therapeutics
- Varun Kushwah, Principal Scientist, Research Center Pharmaceutical Engineering GmbH
- Toria Legh-Land, Computational Pharmaceutics Lead, Microsol
- Sabine Kuratli, CMC Lead, CEPI
- Shilpa Thosar, CMC/Regulatory CMC Executive

#### Academic

- Karsten Mäder, Professor, Martin Luther University Halle-Wittenberg
- Andreas Bernkop-Schnürch, Professor, Innsbruck University
- Kamalinder Singh, Professor of Pharmaceutical Technology & Drug Delivery, University of Central Lancashire
- Moein Moghimi, Professor of Nanomedicine and Pharmaceutics, School of Pharmacy at Newcastle University
- Zeeshan Ahmad, Professor of Pharmaceutics and Drug Delivery, De Montfort University
- Amal Ali Elkordy, Professor, University of Sunderland
- Rene van Nostrum, Professor, Utrecht University
- Yi Sun, Associate Professor, Technical University of Denmark

### Investment & Commercialisation:

- Christoph Rösli, Director of Research Bern, CSL Behring & Member of the Selection Board, BaseLaunch
- David Dexter, Director of Research, Parkinsons UK
- David Jenkinson, Head of Childhood Cancer Translational Challenge, LifeArc
- Oliver May, Managing Director, InnoSyn B.V
- Natasha Drapeau, Managing Director & Co-Founding Senior Partner, Cohesion Bureau
- Duane Schulthess, Chief Executive Officer, Vital Transformation
- Alain Martelli, Director External Science and Innovation France, Discovery Network, Pfizer
- Peng Leong, Chief Business Officer & Head of Brain Aging, BioAge Labs
- Virginia Ballotta, Manager of New Ventures, BaseLaunch
- Bobby Soni, Chief International Officer, BioInnovation Institute
- (Reserved) Sven Verguts, Associate Director Technical Applications ATMPs & Emerging Biotechs, Merck
- (Reserved) Jean Ge, Patent Attorney, Wolf Greenfield

### Innovation & Collaboration & Partnership:

- Lubor Gaal, Chief Financial Officer & Chief Business Officer, Cicio Holdings
- Alexander Natz, Secretary General, EUCOPE
- Emanuele Ostuni, Chief Executive Officer, ARTBIO
- Alain Martelli, Director External Science and Innovation France, Discovery Network, Pfizer
- Anna-Pia Papageorgiou, Policy Officer, Health Innovations, DG Research & Innovation, European Commission

08.00 - 08.50	Registration, Exhibition Opens, Welcome Breakfast					
08.50 - 09.00	Oxford Global's Welcome Address					
09.00 - 09.30	Opening Keynote Address 357 Years Of Science And Innovation CONFIRMED: Ulrich Betz, Vice President Innovation, I	Merck				
09.30 - 09.35	Transition time between conference rooms					
	Small Molecule Formulation	Large Molecule Delivery	Preformulation Studies	RNA Design & Delivery	Start Up Zone Programme	
09.35 - 10.00	<ul> <li>Track Keynote Address:</li> <li>Envisaging the future of long acting injectables and implants</li> <li>LAIs have become an important area of drug development due to their positive effects on patient adherence in various therapeutic areas. However, the development of LAIs presents unique challenges that need to be addressed for successful implementation. In this study, several strategies are discussed to shorten the development timeline. In addition, other factors such as drug substance characteristics, formulation and manufacturing, biomaterials, analytics, and biocompatibility of the LAIs are discussed to minimize the risk of failure in any stage of development. At the end, a patient centric approach is suggested for future development of LAIs</li> </ul>	Track Keynote Address: Novel Delivery Approaches For Biologics	Track Keynote Address: Preformulation Strategies for PROTACs: Adapting to Unique Challenges in early CMC Development • Specific challenges faced in the preformulation phase for PROTACs, and how these differ from standard new chemical entities (NCEs), will be discussed • Focus will be set on challenges regarding physico-chemical profiling, solubility, stability, and biopharmaceutics, including in vitro / in vivo / in silico aspects	Track Keynote Address: Novel Strategies For Drug Delivery	Presentation 1: InnoSyn B.V Oliver May, Managing Director, InnoSyn B.V Presentation 2: TBC	
	Farshad Ramazani, Senior Expert Science & Technology, Novartis	Heinrich Haas, Chief Technology Officer, NeoVac	Holger Kubas, Head of Early Stage Development, Merck	Maria Levitin, Director of RNA Oligonucleotide Delivery, Genetic Medicine, Grünenthal		
10.00 - 11.20	Morning Coffee Break & 1-2-1 Meetings	x4				
11.20 - 11.45	Solution Provider Presentation LONZO Small Molecules	Platinum / Gold Solution Provider Presentation For sponsorship opportunities please contact: <u>sponsorship@oxfordglobal.co</u> <u>m</u>	Solution Provider Presentation	Platinum / Gold Solution Provider Presentation For sponsorship opportunities please contact: <u>sponsorship@oxfordglobal.com</u>	Attendees Are Welcome To Attend Co-Located Sessions	

Small Molecule Formulation	Large Molecule Delivery	Preformulation Studies	RNA Design & Delivery	Spotlight Session
<ul> <li>Panel Discussion:</li> <li>Enhancing Formulations With New</li> <li>Modalities</li> <li>PROTACs</li> <li>Molecular Glues</li> <li>Hot Melt Extrusion (HME)</li> </ul>	Overcoming The Blood-Brain Barrier Moein Moghimi, Professor of Nanomedicine and Pharmaceutics, School of Pharmacy at Newcastle University	Aerosol Characterisation Dan Hardy, Chief Executive Officer. Microsol	Developments With Lipid Based Formulations For Oligonucleotide Delivery Katarzyna Malik, Research and Development Director, Polpharma	Panel Discussion: Women In Discovery & Development: Leading The Charge In Biopharma & Academia
<i>Panellist:</i> Suruchi Vishwasrao, Senior Scientist, Merck Florian Ries, Senior Scientist, AbbVie	Nanoparticle-Based Drug Delivery For Immune Cell Engineering	Technologies For Preformulation Studies In Pharmaceutical Product Development	RNA Processes And Formulations	<ul> <li>women in senior leadership roles</li> <li>Diversity in the discovery &amp; development space</li> <li>How does having more women in leadership improve healthcare outcomes</li> </ul>
	Yi Sun, Associate Professor, Technical University of Denmark	Estelle Beguin, Director Technology Research, Ethris	Covadonga Paneda, Chief Operating Officer, Altamira Therapeutics	and innovation?
Solution Provider Presentation	Solution Provider Presentation	Solution Provider Presentation           REDSHIFT         Bio           See change*         See change*	Silver Solution Provider Presentation Schrödinger	Start Up Presentations 2x
Lunch Poster Presentation Sessions, 1	-2-1 Meetings x3			L
Small Molecule Formulation	Large Molecule Delivery	Preformulation Studies	RNA Design & Delivery	Early-Stage R&D Innovation Programme - Investments & Commercialisation
Solution Provider Presentation	Solution Provider Presentation	Solution Provider Presentation	Solution Provider Presentation CRODA Pharma	Attendees Are Welcome To Attend Co-Located Sessions
	Panel Discussion: Enhancing Formulations With New Modalities PROTACS Molecular Glues Hot Melt Extrusion (HME) Panellist: Suruchi Vishwasrao, Senior Scientist, Merck Florian Ries, Senior Scientist, AbbVie Solution Provider Presentation Solution Provider Presentation Lunch Poster Presentation Sessions, 1 Small Molecule Formulation	Panel Discussion: Enhancing Formulations With New ModalitiesOvercoming The Blood-Brain Barrier• PROTACS • Molecular Glues • Hot Melt Extrusion (HME)Moein Moghimi, Professor of Nanomedicine and Pharmaceutics, School of Pharmacy at Newcastle UniversityPanellist: Suruchi Vishwasrao, Senior Scientist, MerckNanoparticle-Based Drug Delivery For Immune Cell EngineeringFlorian Ries, Senior Scientist, AbbVieYi Sun, Associate Professor, Technical University of DenmarkSolution Provider PresentationSolution Provider PresentationImage: Senior Scientist, Section Sessions, 1-2-1 Meetings x3Curch PresentationSmall Molecule FormulationLarge Molecule DeliverySolution Provider PresentationSolution Provider Presentation	Panel Discussion: Enhancing Formulations With New ModalitiesOvercoming The Blood-Brain BarrierAerosol CharacterisationPROTACSMolecular GluesMoein Moghimi, Professor of Nanomedicine and Pharmaceutics, School of Pharmaceutics, School of School of Pharmaceutics, School of Pharmaceutics, School	Panel Discussion:       Overcoming The Blood-Brain Barrier       Aerosol Characterisation       Developments With Lipid Based Formulations For Oligonucleotide Delivery <ul> <li>PROTACS</li> <li>Molecular Glues</li> <li>Hot Melt Extrusion (HME)</li> </ul> <ul> <li>Panel Discussion:</li> <li>Molecular Glues</li> <li>Hot Melt Extrusion (HME)</li> </ul> <ul> <li>Panel Moghimi, Professor of Nanomedicine and Pharmaceutics, School of Counce and Pharmaceutics, School of Pharmaceutics, School of Inmune Cell Engineering</li> </ul> <ul> <li>Panel Net Kataryan Malik, Research and Development Director, Polpharma</li> <li>RNA Processes And Formulations Studies In Pharmaceutical Product</li> <li>Scientist, Merck</li> <li>Florian Ries, Senior Scientist, AbbVie</li> <li>Yi Sun, Associate Professor, Technical University of Denmark</li> <li>Solution Provider Presentation</li> <li>Solution Provider Presentat</li></ul>

	Small Molecule Formulation	Large Molecule Delivery	Preformulation Studies	RNA Design & Delivery	Early-Stage R&D Innovation Programme – Investments & Commercialisation
14.25 - 14.50	Developments Within Small Molecule Formulation	<ul> <li>Applying Viral Vector Vaccine</li> <li>Learnings to Gene Therapy: To</li> <li>Expect the Unexpected</li> <li>This presentation highlights how over a decade of viral vector vaccine development informs gene therapy advancements</li> <li>Key insights include formulation development, surface interactions, fit-for-purpose analytical methods, modelling, and innovative approaches to create stable, robust gene therapy products</li> </ul>	Exploring Antibubbles For Drug Delivery Applications	Intracellular Delivery Of RNA Therapeutics	Presentation 1: The BaseLaunch Initiative Christoph Rösli, Director of Research Bern, CSL Behring & Member of the Selection Board, BaseLaunch Presentation 2: The Parkinsons Virtual Biotech
	Simone Vecchi, Associate Director, Janssen	Juha Monkare, Principal Scientist, Johnson & Johnson Innovative Medicine	Rene van Nostrum, Professor, Utrecht University	Vineeta Tripathi, Chief Executive Officer, Vitarka Therapeutics	David Dexter, Director of Research, Parkinson's UK
14.50 - 15.15	Solution Provider Presentation	Solution Provider Presentation CRODA Pharma	Silver Solution Provider Presentation For sponsorship opportunities please contact: <u>sponsorship@oxfordglobal.com</u>	Silver Solution Provider Presentation For sponsorship opportunities please contact: <u>sponsorship@oxfordglobal.com</u>	Attendees Are Welcome To Attend Co-Located Sessions
15.15 - 16.15	Afternoon Coffee & Refreshments	, Poster Presentation Sessions, 1-2-1 N	leetings x3	•	
16.15 - 16.40	Solution Provider Presentation	Bronze Level Solution Provider Presentation	Bronze Level Solution Provider Presentation	Bronze Level Solution Provider Presentation	Attendees Are Welcome To
	Leading Beyond Chemistry	For sponsorship opportunities please contact: <u>sponsorship@oxfordglobal.com</u>	For sponsorship opportunities please contact: <u>sponsorship@oxfordglobal.com</u>	For sponsorship opportunities please contact: <u>sponsorship@oxfordglobal.com</u>	Attend Co-Located Sessions

	Small Molecule Formulation	Large Molecule Delivery	Preformulation Studies	RNA Design & Delivery	Early-Stage R&D Innovation Programme – Investments & Commercialisation
16.40 - 17.05	Formulation Of Solubility- Limited Small Molecules: ASD With Hot Melt Extrusion Suruchi Vishwasrao, Senior Scientist, Merck	Workshop: Formulation Development & Delivery For Inhaled Therapies Presentation 1: Inhaled Biologics Formulation And Delivery Tanvir Tabish, Director, Early Formulation Development, AstraZeneca Presentation 2: Considerations In Inhalation Drug Development Stephen Pham, Senior Vice President, Avalyn Pharma Inc.	Workshop: Al/ML In Pre-Formulation Development Studies Presentation 1: Machine Learning And Pre- Formulation Developments Eric Lorent, Principal Scientist, Sanofi Presentation 2: Al And Pre-Formulation Studies Shayoni Dutta, Data Science Manager, GSK	Innovative Technology For RNA Thermostability And Equitable Access Sabine Kuratli, CMC Lead, CEPI	Presentation 1: The C-Further Initiative David Jenkinson, Head of Childhood Cancer Translational Challenge, LifeArc Presentation 2: Strategies For Successful Product Commercialisation Natasha Drapeau, Managing Director & Co- Founding Senior Partner, Cohesion Bureau
17.05 - 17.30	Digitalisation Of In-Silico Modelling For Spray Drying Formulations Andreas Gryczke, Director, Process Engineering, AbbVie			The Changing Landscape Of Non-Liver Delivery Sandor Batkai, Co-Founder, Head of Medical Research and Intelligence, Cardior Pharmaceuticals	Presentation 1: Regulatory & Scaling Pitfalls: The Journey From R&D To The Clinic (Reserved): Sven Verguts, Associate Director - Technical Applications - ATMPs & Emerging Biotechs, Merck Presentation 2: What Keeps Great Start Ups From Securing Funding? Duane Schulthess, Chief Executive Officer, Vital Transformation

	Small Molecule Formulation	Large Molecule Delivery	Preformulation Studies	RNA Design & Delivery	Early-Stage R&D Innovation Programme – <i>Investments &amp;</i> <i>Commercialisation</i>
17.30 - 17.55	Developments Within PROTACs	<ul> <li>Workshop Continued:</li> <li>Formulation Development &amp; Delivery For Inhaled Therapies</li> <li>Panel Discussion:</li> <li>Formulation Development And Characterisation Challenges For Inhalation <ul> <li>Overcoming solubility issues</li> <li>Analytical &amp; characterisation techniques</li> <li>Innovations in inhalation drug delivery</li> <li>Patient-centric considerations</li> </ul> </li> <li><i>Moderator:</i></li> <li>Toria Legh-Land, Computational Pharmaceutics Lead, Microsol</li> <li><i>Panellists:</i></li> <li>Tanvir Tabish, Director, Early Formulation Development, AstraZeneca</li> <li>Enrico Zambelli, Sustainable Formulation Project Unit Manager, Chiesi</li> <li>Amal Ali Elkordy, Professor, University of Sunderland</li> <li>Stephen Pham, Senior Vice President,</li> </ul>	<ul> <li>Panel Discussion Continued: Al/ML &amp; Novel Technologies In Formulation <ul> <li>Applications of Al/ML in formulation</li> <li>Al-driven approaches to optimise dosage forms</li> <li>Al/ML for personalised formulations</li> </ul> </li> <li>Moderator: Shilpa Thosar, CMC/Regulatory CMC Executive</li> <li>Panellists: (Reserved): Eric Lorent, Principal Scientist, Sanofi</li> <li>(Reserved): Shayoni Dutta, Data Science Manager, GSK</li> <li>Karsten Mäder, Professor, Martin Luter University Halle-Wittenberg</li> </ul>	<ul> <li>mRNA Therapies - Spatially Delivered</li> <li>The presentation provides an overview of Panther's approach and accomplishments in modifying the surface chemistry and composition of Lipid Nanoparticles (LNPs) to facilitate their extra-hepatic delivery of mRNAs for therapeutic and immune- related applications.</li> </ul>	Panel Discussion: Breakthrough Biotech: How Research Leaders Fund the Next Big Idea • How research leaders identify and support fundable biotech Innovations • Overcoming early-stage funding gaps in biotech startups • The role of research partnerships with pharma, VCs, and industry in startup success • What startups can learn from research-backed biotech wins Panellists: Bobby Soni, Chief International Officer, Bioinnovation Institute Christoph Rösli, Director of Research Bern, CSL Behring & Member of the Selection Board, BaseLaunch
	Meike Harms, Lead Scientist, Enabling Development, Merck	Avalyn Pharma Inc. (Reserved): Nicolas Schwenck, Business Development Manager, Ebenbuild		Daniel Tondera, Head of Biology, Pantherna Therapeutics	David Jenkinson, Head of Childhood Cancer Translational Challenge, LifeArc
17.55 - 18.20	Challenges With Formulating Therapies Delivered With Liposomes Amal Ali Elkordy, Professor,	Roundtable Discussion 1: Dry Power Inhalers (DPIs) And Metered- Dose Inhalers (MDIs) <i>Moderator:</i> Enrico Zambelli, Sustainable Formulation Project Unit Manager, Chiesi Roundtable Discussion 2: Novel Strategies For Inhalation Therapy Design (Reserved): Stephen Pham, Senior Vice	Roundtable Discussion 1: Using Alternative Drug Delivery Routes Roundtable Discussion 2: Novel Strategies For RNA Design Roundtable Discussion 3: Novel Bioanalytical Methods	Developments Within sRNA Design & Delivery Meiling Li, Principal Scientist, Roche	David Dexter, Director of Research, Parkinsons UK
	Amal Ali Elkordy, Professor, University of Sunderland	For Inhalation Therapy Design (Reserved): Stephen Pham, Senior Vice President, Avalyn Pharma Inc.	Roundtable Discussion 3: Novel Bioanalytical Methods	Meiling Li, Principal Scientist, Roche	

18.20 - 19.00	Small Molecule Formulation End Of Day 1 & Networking Drinks	Large Molecule Delivery	Preformulation Studies	RNA Design & Delivery	Early-Stage R&D Innovation Programme – Investments & Commercialisation
19.00	Networking Dinner 1 Private invite-only hosted dinner. For Sponsorship Opportunities please contact sponsorship@oxfordglobal.com	Networking Dinner 2 Private invite-only hosted dinner. For Sponsorship Opportunities please contact sponsorship@oxfordglobal.com	Networking Dinner 3 Private invite-only hosted dinner. For Sponsorship Opportunities please contact sponsorship@oxfordglobal.com	<b>Networking Di</b> Private invite-only hosted dinner. For please contact <mark>sponsorship@</mark>	Sponsorship Opportunities

### Formulation & Drug Delivery Congress Day Two - 24<sup>th</sup> June 2025

08.00 - 9.30	Roundtable 1:	Workshop 1:	Workshop 2:
	Discovery And Delivery Of Therapeutics Across The Blood Brain Barrier – Where	Translational Challenges In Motor Neuron	SiLA & AnIML Splash
	Are We Now?	Disease – Can We Find A Solution?	Splash! Is a unique event for every digital lab
	Brain Shuttle Platform	10-minute introduction by LifeArc Representative	enthusiast. It combines an educational part wit
	Monocytes	Panel discussion:	a hands-on session to try out standards in
	<ul> <li>Microbubbles</li> <li>Moderator: Shadi Farhangrazi, Chief Executive Officer, S.M. Discovery Group</li> <li>Roundtable 2:</li> <li>High Dose Approved And Sub-Cutaneous Delivered Antibody Products - Formulation And SC Delivery Challenges</li> <li>Formulation trends of high dose SC products</li> <li>SC Delivery challenges</li> <li>Delivery devices</li> <li>Moderator: Ramesh Kashi, Senior Scientific Director Sterile Product</li> </ul>	<ul> <li>How do we tackle these challenges?</li> <li>Are we any closer to a solution?</li> <li>Application of AI/ML</li> </ul> Moderators: Manuela Cerina, Scientific Director – Neurodegeneration, LifeArc Giovanna Lalli, Director of Strategy & Operations, LifeArc	<ul> <li>action. Pick up the details on the popular SiLA and AnIML standards, understand how they work and where you can put them to use. Our hands-on session lets you experience the standards in action firsthand. We're bringing real and cloud-based instruments and lots of example data sets</li> <li>Feel free to bring an instrument or your own data</li> </ul>
	Moderator: Rames Rash, Schor Schenen Schenen Sterne Froduct         Development         Roundtable 3:         IP Considerations In Early Discovery & Development         How to approach IP & set up the correct infrastructure         Protecting a platform vs an asset         Which IP issues should you prioritise?         Moderator: Jean Ge, Patent Attorney, Wolf Greenfield		
	<ul> <li>Roundtable 4:</li> <li>Successes And Pitfalls With AI In Drug Discovery And Development</li> <li>Landscape</li> <li>Future Uses</li> <li>Enhancing Drug Development</li> </ul>		
	<ul> <li>Roundtable 5:</li> <li>PROTACs - Drugging The 'Undruggable'</li> <li>Enhancing PROTAC design, potency &amp; safety</li> <li>Delivery challenges</li> </ul>	LifeArc	
	Roundtable 6:         Sustainability In Formulation Development         • Integrating sustainability into formulation R&D         • Excipients & raw materials		
09.30 - 10.00	Keynote Address:		
	Al-Driven Drug Discovery		

	Solution Provider Presentation  LOCITION Capsules & Health Ingredients  Advancing Protein Particle Strategies in Biological Products: Lessons from an Intra-Company Analysis  Protein aggression and particle formation remain major challenges without a unified biopharmaceutical strategy A cross-functional team at Novartis analysed historical interpretation of the structure	Solution Provider Presentation Solution Provider Presentation BioDuro Panel Discussion: Differing Drug Delivery Strategies And Methods • Drug Delivery via: • Ear • Skin • Eye • Nanoparticles Panellist:	Gold Solution Provider Presentation For sponsorship opportunities please contact: <u>sponsorship@oxfordglobal.com</u> Early-Stage Chemistry To Dry Product Development	Gold Solution Provider Presentation For sponsorship opportunities please contact: sponsorship@oxfordglobal.com Panel Discussion: Moving Beyond Oral Delivery Nanoparticles Inhalation Transdermal Developments with Oral Delivery Moderator: (Reserved) Sandor Batkai, Co- founder, Head of Medical	Attendees Are Welcome To Attend Co-Located Sessions Start Up Zone Presentations x4
	<ul> <li>Strategies in Biological</li> <li>Products: Lessons from an</li> <li>Intra-Company Analysis</li> <li>Protein aggression and particle formation remain major challenges without a unified biopharmaceutical strategy</li> <li>A cross-functional team at Novartis analysed historical</li> </ul>	Differing Drug Delivery Strategies And Methods • Drug Delivery via: • Ear • Skin • Eye • Nanoparticles Panellist:		<ul> <li>Moving Beyond Oral Delivery</li> <li>Nanoparticles</li> <li>Inhalation</li> <li>Transdermal</li> <li>Developments with Oral Delivery</li> <li>Moderator: (Reserved) Sandor Batkai, Co-</li> </ul>	
	<ul> <li>issues, revealing key themes for a particle mitigation strategy</li> <li>The strategy aims to evolve approaches to particle risks, including but not limited to characterization and prevention</li> <li>Sorina Morar-Mitrica, Director Science &amp; Technology, Novartis</li> </ul>	Farshad Ramazani, Senior Expert Science & Technology, Novartis Amal Ali Elkordy, Professor, University of Sunderland	Simone Tortoioli, Senior CMC Director, Monte Rosa Therapeutics	Research and Intelligence, Cardior Pharmaceuticals Panellists: Shadi Farhangrazi, Chief Executive Officer, S.M. Discovery Group Joël Richard, Chief Development Officer, Enterome SA (Reserved): Andreas Bernkop-	
	Formulation Development Strategy For Next Generation Cancer Therapies Saif Shubber, Associate Director, Bicycle Therapeutics		How Multiphysics Prediction Changes The World Of Process Development Florian Ries, Senior Scientist, AbbVie	Schnürch, Professor, Innsbruck University	
11.20 - 11.45	Silver Solution Provider Presentation For sponsorship opportunities please contact: <u>sponsorship@oxfordglobal.com</u>	Solution Provider Presentation	Silver Solution Provider Presentation For sponsorship opportunities please contact: <u>sponsorship@oxfordglobal.com</u>	Silver Solution Provider Presentation For sponsorship opportunities please contact: <u>sponsorship@oxfordglobal.com</u>	Attendees Are Welcome To Attend Co-Located Sessions

	Large Molecule Formulation	Small Molecule Drug Delivery	Process Chemistry & Pharmaceutical Materials Analysis	Peptide & Oligo Design & Delivery	Early-Stage R&D Innovation Programme – Collaborations & Partnerships
12.45 - 13.10	Solution Provider Presentation	Solution Provider Presentation	Bronze Solution Provider Presentation For sponsorship opportunities please contact: <u>sponsorship@oxfordglobal.com</u>	Bronze Solution Provider Presentation For sponsorship opportunities please contact: <u>sponsorship@oxfordglobal.com</u>	Attendees Are Welcome To Attend Co-Located Sessions
13.10 - 13.35	Enhancing Stability Of Excipients To Improve APIs Supriyadi Hafiz, Senior Scientist, Merck	Challenges With Nanotechnology Approaches Jessica Yu, Senior Scientist, AstraZeneca	Novel Techniques In Product Development Zeeshan Ahmad, Professor of Pharmaceutics and Drug Delivery, De Montfort University	Challenges Of Long-Acting Injectable Delivery Of Peptide And Proteins Joël Richard, Chief Development Officer, Enterome SA	Presentations 1: How The New EU Legislative Environment Can Shape Drug Development And Access In Europe Alexander Natz, Secretary General, EUCOPE Presentation 2: Pfizer Discovery Network: Harnessing External Innovation To Deliver Breakthroughs Alain Martelli, Director External Science and Innovation - France, Discovery Network, Pfizer
13.35 - 14.00	Bronze Level Solution Provider Presentation For sponsorship opportunities please contact: <u>sponsorship@oxfordglobal.com</u>	Solution Provider Presentation CAPTISOL® BROUGHT TO YOU BY LIGAND PHARMACEUTICALS	Bronze Solution Provider Presentation For sponsorship opportunities please contact: <u>sponsorship@oxfordglobal.com</u>	Bronze Solution Provider Presentation For sponsorship opportunities please contact: <u>sponsorship@oxfordglobal.com</u>	Attendees Are Welcome To Attend Co-Located Sessions
14.00 - 15.00	Lunch, Poster Presentation Session	ns, 1-2-1 Meetings x3	•	•	•

Large Molecule Formulation	Small Molecule Drug Delivery	Process Chemistry & Pharmaceutical Materials Analysis	Peptide & Oligo Design & Delivery	Early-Stage R&D Innovation Programme – <i>Collaborations &amp;</i> Partnerships
Developing New Biotherapeutic Modalities While Ensuring Robustness And Quality In Their Formulations • Improve the stability profile of	Therapies	<ul> <li>Analytical Characterization And</li> <li>Stability</li> <li>APIs</li> <li>Excipients</li> <li>Blends</li> </ul>	Barriers With Oligo Delivery	And Opportunities In Radiopharma Emanuele Ostuni, Chief Executive Officer, ARTBIO
<ul> <li>biomolecules</li> <li>New excipients</li> <li>Impact on product quality and stability</li> <li>Alternative ways of formulation <i>Panellists:</i></li> <li>Ramesh Kashi, Senior Scientific Director Sterile Product Development</li> </ul>		• Final Solid Dosage Forms		Presentation 2: EU Funding Programme on ATMPs Anna-Pia Papageorgiou, Policy Officer, Health Innovations, DG Research & Innovation, European Commission
Tanvir Tabish, Director, Early Formulation Development, AstraZeneca	Kamalinder Singh, Professor of Pharmaceutical Technology & Drug Delivery		Vik Reebye, Senior Principal Scientist, Head of Academic Partnership, MiNA Therapeutics	

### Formulation & Drug Delivery Congress Day Two - 24<sup>th</sup> June 2025

	Large Molecule Formulation	Small Molecule Drug Delivery	Process Chemistry & Pharmaceutical Materials Analysis	Peptide & Oligo Design & Delivery	Early-Stage R&D Innovation Programme – <i>Collaborations &amp;</i> Partnerships
15.25 - 15.50	Hybrid Formulation Approaches	<ul> <li>Drug Delivery To The Inner Ear: Need, Challenges And New Developments</li> <li>Currently unmet medical need for drug delivery to the inner ear</li> <li>Advantages and challenges of intratympanic and intracochlear delivery will be discussed</li> <li>In vivo data of intracochlear delivery systems will be presented</li> </ul>	Selection And Manufacturing Of API	Peptide Delivery Via Long- Acting Injectables	<ul> <li>Panel Discussion: Fostering Partnerships &amp; Collaboration In 2025</li> <li>Emerging technologies &amp; techniques</li> <li>Cross-sector partnership</li> <li>Open innovation</li> <li>Moderator: Alexander Natz, Secretary General, EUCOPE</li> <li>Panellists: Lubor Gaal, Chief Financial Officer &amp; Chief Business Officer, Cicio Holdings Peng Leong, Chief Business Officer &amp; Head of</li> <li>Brain Aging, BioAge Labs Anna-Pia Papageorgiou, Policy Officer, Health Innovation, DG Research &amp; Innovation, European Commission Alain Martelli, Director External Science and Innovation - France, Discovery Network, Pfizer</li> </ul>
	Jens Twellmeyer, Associate Director Science & Technology at Novartis	Karsten Mäder, Professor, Martin Luter University Halle-Wittenberg	Sophie Janbon, Director, AstraZeneca	Tjasa Vrlinic, Principal Investigator, Medincell	
15.50 - 16.15	High Dosage Biologics Formulation Ramesh Kashi, Senior Scientific Director	Developments With Implant Delivery Varun Kushwah, Principal Scientist, Research Center	Sustainable Inhalation Devices – The Challenges Of Meeting Net Zero Global Emissions Enrico Zambelli, Sustainable Formulation Project Unit	Oral Delivery Of Peptide And Protein Drugs - Oral Delivery Of GLP-1 Analogues • Barriers to the Oral Administration of Peptide and Protein Drugs • Development of Self- Emulsifying Delivery Systems for GLP-1 Analogues • Oral Bioavailability of GLP-1 Analogues: What is Achievable? Andreas Bernkop-Schnürch, Professor, Innsbruck University	
	Sterile Product Development	Pharmaceutical Engineering	Manager, Chiesi	University	
16.15	End of Congress				